by Raynovich Rod | Jun 24, 2015 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Updated 6/25 Precision Medicine -Novel Prevention and Treatment Strategies Lead The Way A New Initiative on Precision Medicine — NEJM Over 15,000 attended BIO 2015 in Philadelphia including 1100 companies and more than 30 nations. The Exhibits and Partnering meetings...
by Raynovich Rod | Jun 12, 2015 | BIOgraph
We will be attending the BIO International Convention in Philadelphia next week. Sign up now to receive life science industry news.
by Raynovich Rod | Sep 18, 2013 | BIOgraph
No Taper Rallies Stocks and Bonds-Equities up almost 1% Most sectors and stocks turned bright green after FED announces “No Taper”. Biotech stocks are up with IBB up 1%. Drug stocks very strong due to dividend plays and lower 10 year yield (2.724%). Gold...
by Raynovich Rod | Sep 17, 2013 | BIOgraph
Chin-Up and Out! KYTH traded 2.58M shares today closing near its gap up 25% this morning at $41.95 . There was distribution of stock probably from early investors to funds and retail. The market cap is $774M. As of June 30,2013 reporting the Company had Shareholder...
by Raynovich Rod | Jun 24, 2013 | BIOgraph
Life Science Stocks in Corrective Mode-Look for Support Today Update-winners could not hold tops with IBB ending day at $167, NASDAQ at 3321 The sector sell-off which began off the May top (up 30%) and picked up downward momentum in June is continuing today....
by Raynovich Rod | Jun 19, 2013 | BIOgraph, Macro
Downside Risk to Economy Diminished So Less “Extreme Monetary Policy” In the Future? Market Stable with downward bias :S&P flat to down 18 pts-10 Year Bond Yield At 2.28% up 3.9% FED Is Optimistic about the economy: housing, consumer sentiment,...
by Raynovich Rod | Jun 14, 2013 | BIOgraph, Biopharmaceuticals
Biotech Sell-Off Continues Nothing dramatic but the overall weakness in biopharmaceutical stocks is continuing today despite a strong performance by NASDAQ up 1.2% at 3464. With biotech having one of it best years of all time, profit taking is expected. The most...
by Raynovich Rod | Jun 13, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction...
by Raynovich Rod | Jun 11, 2013 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the...
by Raynovich Rod | Jun 5, 2013 | BIOgraph, Biopharmaceuticals
Market Correction Is Here-IBB at 170 off 2%+ The biotech sector sell-off (IBB at $170) continues today despite an effort to rally in the opening (IBB at $178). The biotech sector now tracks the overall market and is no longer immune to macro issues and economic...
